BRILLIANT BLUE G - Generic Drug Details

✉ Email this page to a colleague

What are the generic sources for brilliant blue g and what is the scope of patent protection?

Brilliant blue g is the generic ingredient in one branded drug marketed by Dutch Ophthalmic and is included in one NDA. Additional information is available in the individual branded drug profile pages.

One supplier is listed for this compound.

Summary for BRILLIANT BLUE G

US Patents:	0
Tradenames:	1
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	91
Clinical Trials:	7
Patent Applications:	2,398
What excipients (inactive ingredients) are in BRILLIANT BLUE G?	BRILLIANT BLUE G excipients list
DailyMed Link:	BRILLIANT BLUE G at DailyMed

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for BRILLIANT BLUE G

Generic Entry Date for BRILLIANT BLUE G^: ⤷ Sign Up* Constraining patent/regulatory exclusivity: INDICATED TO SELECTIVELY STAIN THE INTERNAL LIMITING MEMBRANE (ILM) Dosage: SOLUTION;OPHTHALMIC

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for BRILLIANT BLUE G

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Chengdu Brilliant Pharmaceutical Co., Ltd.	Phase 3
Xinhua Hospital, Shanghai Jiao Tong University School of Medicine	N/A
Anthera Pharmaceuticals	Phase 3

See all BRILLIANT BLUE G clinical trials

Pharmacology for BRILLIANT BLUE G

Drug Class	Disclosing Agent
Mechanism of Action	Dyes

US Patents and Regulatory Information for BRILLIANT BLUE G

+ Get email alerts for changes to this table

Glossary

Subscribe to access the full database, or Sign Up
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Dutch Ophthalmic	TISSUEBLUE	brilliant blue g	SOLUTION;OPHTHALMIC	209569-001	Dec 20, 2019		RX	Yes	Yes	⤷ Sign Up	⤷ Sign Up				⤷ Sign Up
Dutch Ophthalmic	TISSUEBLUE	brilliant blue g	SOLUTION;OPHTHALMIC	209569-001	Dec 20, 2019		RX	Yes	Yes	⤷ Sign Up	⤷ Sign Up				⤷ Sign Up
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Summary for BRILLIANT BLUE G

DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for BRILLIANT BLUE G

Recent Clinical Trials for BRILLIANT BLUE G

Pharmacology for BRILLIANT BLUE G

Make Better Decisions: Try a trial or see plans & pricing

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for BRILLIANT BLUE G